Naver Stock Price Plunges 5.56% to 210,000-Won Range... Circuit Breakers Triggered on Both KOSPI and KOSDAQ
On the afternoon of the 28th, Naver's stock price fell by more than 5%, dropping to the 210,000-won range. On the same day, the broader domestic stock market re

On the afternoon of the 28th, Naver's stock price fell by more than 5%, dropping to the 210,000-won range. On the same day, the broader domestic stock market recorded a sharp decline, with circuit breakers triggered simultaneously on both the KOSPI and KOSDAQ.
As of 12:48 p.m. on this day, Naver was trading at 212,500 won, down 12,500 won (5.56%) from the previous trading day. It has been extending its losses throughout the session, continuing a bearish trend.
At the same time, the KOSPI plunged 636.65 points (9.42%) from the previous trading day to 6,119.10, while the KOSDAQ was trading down 57.80 points (7.55%) at 707.06.
As market shock widened, the Korea Exchange triggered the first-stage Circuit Breaker (CB) on the KOSPI. On the KOSDAQ, emergency measures followed in succession, with a Circuit Breaker triggered in addition to a temporary suspension of program sell orders (Sidecar).
On the same day, as massive sell-offs by foreigners and institutions swept the domestic stock market, most of the top market-cap stocks faced downward pressure. The mixed performance of the U.S. stock market the previous day, driven by weakness in the semiconductor sector, also played a role.
Naver was no exception, unable to avoid a bearish trend as a risk-off sentiment spread across the broader market, drawing in sell orders.
The market views whether domestic stock market volatility will ease in the near term as a key factor that will determine the stock price movements of large-cap tech stocks, including Naver. In particular, attention is focused on whether Naver can defend the 210,000-won support level.
[※ This article is not a solicitation to invest, and the responsibility for investment decisions lies with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking News] ABL Bio's ABL503 Phase 1 Clinical Trial Receives Additional Approval from Korea's MFDS Following U.S. FDA](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579545%2F36de0fb87055dd02%2Fvariants%2Fhero.webp&w=1920&q=75)


![[Breaking] Oriental Precision (014940) Surges Over 10% Amid KOSPI and KOSDAQ Decline... Static VI Triggered](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581419%2F479dac739b049517%2Fvariants%2Fhero.webp&w=1920&q=75)